<DOC>
	<DOCNO>NCT00944034</DOCNO>
	<brief_summary>This extension study V72P12E1 investigate safety , tolerability immunogenicity fourth ( booster ) dose rMenB+OMV NZ 12 , 18 24 month age subject previously prim rMenB+OMV NZ accord two different three-dose immunization schedule infancy ( 2 , 4 6 2 , 3 4 month age parent study V72P12 ) . The study also explore bactericidal antibody persistence 12 , 18 24 month age , follow two different immunization schedule , order identify optimal timing boost . Two catch-up rMenB+OMV NZ dose give unprimed , na√Øve toddler 12 ( subject enrol control group V72P12 ) , 18 24 month age ( two new cohort subject enrol ) . These subject generate data assess safety immunogenicity two-dose catch-up regimen age , also serve control descriptive comparison antibody persistence booster responses group .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Meningococcal B Recombinant Vaccine Administered Booster Dose 12 , 18 24 Months Age Toddlers ( 12-24 Months ) Primed With Three-Dose Immunization Series Infants Study V72P12</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Followon participant V72P12 : Healthy toddler complete Study V72P12 , age : 12 month old Groups 1a , 2a , 3a , 4 18 month ( 0/ +29 day window ) Groups 1b , 2b , 3b 24 month ( 0/ +29 day window ) Groups 1c , 2c , 3c Naive subject newly enrol : Group 5 : healthy 18monthold toddler ( 0/ +29 day window ) Group 6 : healthy 24monthold toddler ( 0/ +29 day window ) History meningococcal B vaccine administration ( group 5 6 ) ; Previous ascertain suspected disease cause N. meningitidis ; History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Significant acute chronic infection within previous 7 day axillary temperature major equal 38 degree within previous day Antibiotics within 6 day prior enrollment ; Any serious chronic progressive disease ; Known suspect impairment alteration immune system ; Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
	<keyword>toddler</keyword>
</DOC>